Case: Syneos Health, Inc.
Contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NEW YORK, NY – February 28, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Syneos Health, Inc. (Nasdaq: SYNH).  

On February 27, 2019, after the close of trading, the Company announced that it has delayed its previously announced earnings release and conference call to allow additional time to complete its Form 10-K for the year ended December 31, 2018. 

In a filing with the U.S. Securities and Exchange Commission, the Company stated that it “has determined that additional time is needed for management to conduct a review of the Company’s internal control over financial reporting in conjunction with the finalization of the Company’s Form 10-K. On February 21, 2019, the Company received notification from the SEC that it has commenced an investigation into the Company’s revenue accounting policies, internal controls and related matters, and the SEC has requested that the Company retain certain documents for the periods beginning with January 1, 2017. The Company is fully cooperating with the SEC.”

“As an additional measure prior to the Company filing the Form 10-K, the Audit Committee of the Company’s Board of Directors, with the assistance of outside counsel and accounting advisors, is conducting an independent review of the Company’s revenue accounting policies, internal controls and related matters.”

According to the Wall Street Journal, shares of Syneos Health, “which had closed up 0.8% before the announcement and were then paused, tumbled more than 27% to $37.75 when after-hours trading resumed.”  After the opening of trading on February 28, 2019, shares of Syneos declined as much as $14.10 per share or approximately 27%.  

If you purchased Syneos securities, and would like to discuss our investigation, please contact us by emailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by calling 800-290-1952.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about your rights, or your interests, please contact: 

Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400 
San Francisco, California  94104
(415) 772-4700
Fax:  (415) 772-4707
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it